
Aclaris Therapeutics (ACRS) Stock Forecast & Price Target
Aclaris Therapeutics (ACRS) Analyst Ratings
Bulls say
Aclaris Therapeutics Inc has a promising outlook due to its focus on novel drug candidates targeting immuno-inflammatory diseases, with a significant portion of its revenue stemming from the therapeutics segment. Early data for its drug candidate Bosakitug indicates that it may exhibit improved efficacy compared to established treatments like Dupixent, which enhances its competitive position in the market. Additionally, positive patient reported outcomes, including significant improvements in secondary endpoints such as the loss-of-smell score and sleep domain metrics, further bolster the potential for successful product development and future revenue growth.
Bears say
Aclaris Therapeutics Inc demonstrates a concerning outlook as major clinical endpoints show limited efficacy, with only 9% of patients in two cohorts experiencing a meaningful reduction in pruritus, while 50% of patients in another cohort achieved a similar reduction. Additionally, the efficacy data from the placebo group reveals a substantial 39.7% reduction in the EASI score, raising concerns about the comparative effectiveness of Aclaris's treatments. The company's reliance on its therapeutics segment for revenue is further jeopardized by these disappointing clinical trial results, potentially undermining investor confidence in its product pipeline.
This aggregate rating is based on analysts' research of Aclaris Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Aclaris Therapeutics (ACRS) Analyst Forecast & Price Prediction
Start investing in Aclaris Therapeutics (ACRS)
Order type
Buy in
Order amount
Est. shares
0 shares